In a phase III NRG‑GY018 trial investigating Keytruda (pembrolizumab) in combination with standard of care chemotherapy (carboplatin and paclitaxel) for the first-line treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient, the Keytruda regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients, regardless of mismatch repair status.
Tumors with alterations in any of three specific genes were more likely than other tumors to be eliminated by cisplatin-based chemotherapy.
